Denali Therapeutics Inc (DNLI)
Healthcare
Biotechnology
23.00 $
-5.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Denali Therapeutics Inc (DNLI)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 90.9% of the shares are freely tradable; institutional investors hold 99.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
99.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
9.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
90.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
159Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 8.23 | 13,057,890 | +8.9 | 12/31/2025 |
| BlackRock Inc | 8.21 | 13,034,434 | +2.5 | 03/31/2026 |
| Baillie Gifford & Co Limited. | 7.60 | 12,066,479 | -2.0 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 5.37 | 8,519,192 | +0.2 | 03/31/2026 |
| Temasek Holdings Ltd. | 4.42 | 7,012,974 | +0.0 | 03/31/2026 |
| State Street Corp | 3.95 | 6,272,001 | +0.1 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.87 | 6,147,957 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 3.86 | 6,120,160 | +0.0 | 03/31/2026 |
| NORGES BANK | 3.23 | 5,119,622 | +29.7 | 12/31/2025 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Scottish Mortgage Ord | 4.44 | 7,041,270 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.